Mologen up on mCRC data

Mologen AG (Xetra:MGN) jumped EUR 1.90 (20%) to EUR 11.40 on Monday after twice-weekly MGN1703 as maintenance therapy met the primary endpoint of median progression-free survival vs. placebo in the Phase II IMPACT trial to treat metastatic colorectal cancer (mCRC). Specifically, median PFS in an undisclosed predefined target population of 46 patients showed that MGN1703 more than doubled median PFS vs. placebo (p<0.02). Based on the data, Mologen prematurely stopped enrollment in the trial at 58 patients. Overall survival (OS) data will continue to be collected. The trial had planned to enroll 129 patients who had disease stabilization or partial or complete remission of their cancer after receiving first-line therapy with chemotherapy plus Avastin bevacizumab for 4.5-6 months. MGN1703 is a toll-like receptor 9 (TLR9) agonist based on the company's double Stem Loop Immunomodulator (dSLIM) technology. ...